Halozyme Therapeutics, Inc. (HALO) is near the middle in its industry group according to InvestorsObserver. HALO gets an overall rating of 38. That means it scores higher than 38 percent of stocks. Halozyme Therapeutics, Inc. gets a 47 rank in the Biotechnology industry. Biotechnology is number 93 out of 148 industries.
HALO has an Overall Score of 38. Find out what this means to you and get the rest of the rankings on HALO!
What do These Ratings Mean?
Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.
What's Happening With Halozyme Therapeutics, Inc. Stock Today?
Halozyme Therapeutics, Inc. (HALO) stock is trading at $41.99 as of 10:40 AM on Friday, Sep 17, a drop of -$0.06, or -0.14% from the previous closing price of $42.05. Volume today is below average. So far 241,123 shares have traded compared to average volume of 750,844 shares. The stock has traded between $41.55 and $42.68 so far today.
Click Here to get the full Stock Report for Halozyme Therapeutics, Inc. stock.